Background: The pathologic diagnosis and Gleason grading of prostate cancer are timeconsuming, error-prone, and subject to interobserver variability. Machine learning offers opportunities to improve the diagnosis, risk stratification, and prognostication of prostate cancer. Objective: To develop a state-of-the-art deep learning algorithm for the histopathologic diagnosis and Gleason grading of prostate biopsy specimens. Design, setting, and participants: A total of 85 prostate core biopsy specimens from 25 patients were digitized at 20Â magnification and annotated for Gleason 3, 4, and 5 prostate adenocarcinoma by a urologic pathologist. From these virtual slides, we sampled 14 803 image patches of 256 Â 256 pixels, approximately balanced for malignancy. Outcome measurements and statistical analysis: We trained and tested a deep residual convolutional neural network to classify each patch at two levels: (1) coarse (benign vs malignant) and (2) fine (benign vs Gleason 3 vs 4 vs 5). Model performance was evaluated using fivefold cross-validation. Randomization tests were used for hypothesis testing of model performance versus chance. Results and limitations: The model demonstrated 91.5% accuracy (p < 0.001) at coarselevel classification of image patches as benign versus malignant (0.93 sensitivity, 0.90 specificity, and 0.95 average precision). The model demonstrated 85.4% accuracy (p < 0.001) at fine-level classification of image patches as benign versus Gleason 3 versus Gleason 4 versus Gleason 5 (0.83 sensitivity, 0.94 specificity, and 0.83 average precision), with the greatest number of confusions in distinguishing between Gleason 3 and 4, and between Gleason 4 and 5. Limitations include the small sample size and the need for external validation. Conclusions: In this study, a deep learning-based computer vision algorithm demonstrated excellent performance for the histopathologic diagnosis and Gleason grading of prostate cancer. Patient summary: We developed a deep learning algorithm that demonstrated excellent performance for the diagnosis and grading of prostate cancer.
1.

Introduction
Accurate pathologic diagnosis and Gleason grading of prostate cancer are essential for risk stratification and appropriate management [1, 2] but these tasks are time-consuming and subject to substantial interobserver variability [3, 4] . Machine learning offers opportunities to improve the diagnosis, risk stratification, and prognostication of prostate cancer through enhanced classification and prediction in a variety of clinical applications [5] . Recent advances in deep learning methods, fueled by increased computing power and the availability of large data sets, have facilitated remarkable progress in the field of computer vision [6, 7] . For instance, in the CAMEL-YON16 challenge, some deep learning algorithms demonstrated better performance than human pathologists at detecting breast cancer metastases in whole-slide images of lymph nodes [8] .
Although deep learning algorithms have the potential to improve the diagnosis, Gleason grading, and prognostication of prostate cancer, attempts to do so have been limited [9] [10] [11] [12] [13] [14] . Moreover, to the best of our knowledge, only one study used prostate core biopsy specimens for training [9] . Given that initial diagnosis and treatment selection are based on core biopsy pathology [15] , a deep learning algorithm to improve diagnosis and Gleason grading specifically in core biopsy specimens would have profound clinical applications. We therefore conducted a pilot study to develop a deep learning algorithm for the histopathologic diagnosis and Gleason grading of prostate core biopsy specimens.
2.
Patients and methods
Study cohort
After obtaining institutional review board approval, we identified 25 patients from the Miriam Hospital institutional pathology database who underwent !12-core transrectal ultrasound-guided prostate biopsy from January 2011 to November 2012 with a diagnosis of prostate cancer. we report performance on predictions from concatenated validation sets.
Slide digitization and annotation
Model performance was evaluated using fivefold cross-validation over unique patients and is reported as accuracy, sensitivity, specificity, and average precision (weighted area under the precision-recall curve) [17] . Randomization tests were used for hypothesis testing of the model performance against chance [18] . This involved generating a null distribution of the model performance by recalculating model accuracy after
shuffling the associations between its predictions and image patch labels. Null distributions consisted of 10 000 such simulations, and p values were calculated as the proportion of simulations that exceeded the true model accuracy.
Models were trained and evaluated using Tensorflow v.1.5 (www.
tensorflow.org).
Results
Pathologic characteristics for the 85 annotated slides and 14 803 patches of 256 Â 256 pixels are presented in Table 1 . The CNN was separately trained for patch-based classification as (1) benign versus malignant (coarse classification) and (2) benign versus Gleason 3 versus Gleason 4 versus Gleason 5 (fine classification). The model demonstrated 91.5% accuracy for coarse classification of image patches as benign versus malignant (p < 0.001). This corresponded to sensitivity of 0.93, specificity of 0.90, and average precision of 0.95 (Fig. 1) . The AUC was 0.83.
The model demonstrated 85.4% accuracy for fine classification of image patches as benign versus Gleason 3 versus Gleason 4 versus Gleason 5 (p < 0.001). This corresponded to sensitivity of 0.83, specificity of 0.94, and average precision of 0.83 ( Fig. 2) , with the greatest number of confusions in distinguishing between Gleason 3 and 4, and between Gleason 4 and 5. 
Discussion
The deep learning algorithm developed in this pilot study demonstrated remarkably high accuracy in both coarse (benign vs malignant) and fine (benign vs Gleason 3 vs Gleason 4 vs Gleason 5) classification tasks. Although there was some misclassification of Gleason patterns 3, 4, and 5, as seen in the confusion matrix in Fig. 2 , these rates were well within the rate of interobserver variability among human pathologists of 15-30% [3, 4] . Moreover, we observed high performance for a relatively small sample size (relative to the size of machine learning data sets). Few groups have attempted to develop deep learning algorithms for the diagnosis and/or Gleason grading of prostate cancer, almost all using prostatectomy specimens, with modest performance reported [9] [10] [11] [12] [13] [14] . Two groups used tissue microarrays derived from radical prostatectomy specimens to develop patch-based deep learning algorithms for prostate cancer diagnosis and Gleason grading [11, 13] . Nir et al. [13] reported accuracy of 92% for classification of benign versus malignant and 78% for classification of benign versus low-grade versus high-grade (Gleason 4-5) cancer. Arvaniti et al. [11] reported precision (ie, correct prediction with at least one of two pathologist labels) of 58% for benign patches, 75% for Gleason 3, 86% for Gleason 4, and 58% for Gleason 5. Zhou and colleagues [12] used 380 prostatectomy whole-slide images from The Cancer Genome Atlas (TCGA) to differentiate Gleason 3 + 4 from 4 + 3 with accuracy of 75%. Using one of the largest prostatectomybased data sets comprising 1226 annotated slides from TCGA, single-institution samples, and an independent medical laboratory, Nagpal and colleagues [14] trained a deep learning algorithm that had a mean accuracy of 70% compared with 61% among 29 general pathologists.
Importantly, to the best of our knowledge, only one other group has trained a deep learning algorithm specifically using prostate core biopsy specimens. Campanella and coauthors [9] used 12 160 whole-slide images from prostate core biopsies to train a semi-supervised deep learning algorithm that had an AUC of 0.98. Their impressive results appear to stand out when compared to the performance of the prostatectomy-based studies discussed above [11] [12] [13] [14] .
Interestingly, Bartels and colleagues [19] [20] [21] reported on the development of a machine vision system for the diagnosis of prostate cancer and identification of cribriform pattern more than 20 years ago. Although in many respects the work was ahead of its time, there are important distinctions compared to contemporary methods in computer vision. Specifically, contemporary deep learning approaches are a form of "representation learning" that is entirely data driven rather than relying on individual features engineered by humans, as was common in earlier computer vision approaches [6] . The models are therefore not biased towards selection of particular features and may identify novel features that result in both better performance and application to a diverse array of image classification problems.
The distinction between deep learning algorithms based on prostatectomy specimens and those based on core biopsy is a clinically salient one for many reasons. Specifically, the initial diagnosis, risk stratification, and treatment decisions for men with prostate cancer are based on core biopsy pathology [15] . Accordingly, the performance of algorithms developed for prostatectomy specimens may not directly transfer to core biopsy specimens given the markedly smaller tissue specimen and potential for oblique core sampling to alter histologic architecture.
There are other potential applications of a deep learning algorithm that improves the diagnosis and Gleason grading of prostate core biopsy given its central role in the evaluation and management of prostate cancer. For instance, such an algorithm might expand access to expert pathologic diagnosis not only across the USA but globally to regions where access to high-quality health care may be limited [22] . In settings with established pathologic expertise, such a system could be used to minimize human error as part of quality assurance/improvement efforts. Moreover, deep learning algorithms have the potential not only to recapitulate pathologic diagnosis and contemporary Gleason grading systems but also to discover novel morphological features that are relevant to cancer prediction and prognostication, thereby improving performance.
One important consideration for application of such a deep learning model at other centers relates to image preprocessing. The image patches in this study required preprocessing (ie, to have zero mean unit variance) and use of the model in other centers would require fine-tuning to account for potential differences in such parameters given potential differences in tissue preparations, microscopes used, etc. However, with such adjustments it should be possible, in principle, to analyze any digitized prostate biopsy specimen with the model developed here.
This pilot study has a number of limitations. Foremost, it represents results from a small, single-institution cohort; thus, the algorithm will improve with additional training data and it requires external validation. In addition, the algorithm produces patch-based predictions, although extension to a core-based system would not require substantial technical modifications. Furthermore, the deep learning model was not trained to differentiate specific morphological subtypes of Gleason pattern 4, which may have biological implications. Finally, although each slide was re-reviewed by a urologic pathologist, the study would benefit from multiple experts to generate consensus-based ground truth labels. Despite these limitations, the pilot study provides compelling data supporting the feasibility and utility of a deep learning algorithm for the diagnosis and Gleason grading of prostate core biopsy specimens.
Additional studies are currently ongoing to extend these results and examine other clinically relevant outcomes.
Conclusions
In this pilot study, a deep learning-based computer vision algorithm demonstrated excellent accuracy for histopathologic diagnosis and Gleason grading of prostate cancer. These results are encouraging for future clinical application of automated histopathologic diagnosis with deep learning. Obtaining funding: Kott, Linsley, Golijanin, Serre, Gershman.
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